Renovaro Balance Sheet Health
Financial Health criteria checks 2/6
Renovaro has a total shareholder equity of $43.6M and total debt of $7.2M, which brings its debt-to-equity ratio to 16.5%. Its total assets and total liabilities are $58.0M and $14.4M respectively.
Key information
16.5%
Debt to equity ratio
US$7.18m
Debt
Interest coverage ratio | n/a |
Cash | US$243.98k |
Equity | US$43.60m |
Total liabilities | US$14.42m |
Total assets | US$58.02m |
Recent financial health updates
Recent updates
Enochian stock climbs on US patent for oncology platform
Oct 17Enochian BioSciences discovers two sets of altered animal data in two of its studies
Jul 01Is Enochian Biosciences (NASDAQ:ENOB) Using Debt Sensibly?
Jun 28Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?
Feb 20Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?
Oct 30Enochian Biosciences: A Follow Through For An HIV Cure
Jun 26Enochian Biosciences shares skyrocket after FDA accepts Pre-IND request for HIV treatment
Jun 14Do Insiders Own Lots Of Shares In Enochian Biosciences, Inc. (NASDAQ:ENOB)?
Feb 14Financial Position Analysis
Short Term Liabilities: RENB's short term assets ($2.4M) do not cover its short term liabilities ($13.8M).
Long Term Liabilities: RENB's short term assets ($2.4M) exceed its long term liabilities ($664.2K).
Debt to Equity History and Analysis
Debt Level: RENB's net debt to equity ratio (15.9%) is considered satisfactory.
Reducing Debt: RENB's debt to equity ratio has increased from 0% to 16.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RENB has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: RENB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 15% each year